Experience with bilastine in the management of urticaria: Original Real-world cases of Bilastine In Treatment (ORBIT) in Asia

Drugs in Context

article

Wai Kwong Cheong¹  Alson Wai Ming Chan²  Chin Chwen Ch’ng³  Wen Hung Chung⁴  Ma Teresita Gabriel⁵  Kiran Godse⁶  Wat Mitthamsiri⁷  Hao Trong Nguyen⁸  Marysia Tiongco-Recto⁹  Dinesh Nagrale^1,10 

[1] Specialist Skin Clinic & Associates Pte Ltd;Allergy Centre, Hong Kong Sanatorium & Hospital;Subang Jaya Medical Centre;Department of Dermatology, Chang Gung Memorial Hospital;Department of Dermatology, Research Institute for Tropical Medicine;Department of Dermatology, DY Patil University School of Medicine;Allergy and Clinical Immunology Division, Department of Medicine, Phramongkutklao Hospital;Ho Chi Minh City Hospital of Dermato-Venereology;Allergy and Immunology, University of the Philippines – Philippine General Hospital;A. Menarini Asia-Pacific Pte Ltd

关键词: Asia;    bilastine;    case studies;    chronic spontaneous urticaria;    eczema/dermatitis;    H1-antihistamine;    inducible urticaria;    real-world evidence;   

DOI  :  10.7573/dic.2021-12-2

学科分类：社会科学、人文和艺术（综合）

来源: C S F Medical Communications Ltd.

【 摘 要 】

Urticaria is a disabling condition, resulting in an impaired quality of life and sleep disruption, and can have an adverse impact on work-related or school-related performance and attendance. It is defined according to the presence of unknown (chronic spontaneous urticaria) or known (inducible urticaria) eliciting factors. Guidelines recommend second-generation H1-antihistamines for the first-line treatment of urticaria. Bilastine is indicated in adults, adolescents (aged ≥12 years) and children (aged ≥2 years (Mexico and some African countries), ≥4 years (Canada) or ≥6 years (Europe)) with a body weight of at least 20 kg for the symptomatic treatment of urticaria and allergic rhino-conjunctivitis. The aim of the Original Real-world cases of Bilastine In Treatment (ORBIT) study was to review real-world cases from across the Asia-Pacific region supported by evidence-based literature. Eight diverse, real-world, difficult-to-treat cases with urticaria in people aged 10–75 years are presented. Once-daily bilastine (20 mg (adults/adolescents) or 10 mg (children)) was found to be well tolerated and effective in the long-term management of chronic spontaneous urticaria and inducible urticaria.

【 授权许可】

CC BY-NC-ND